Madrigal Pharmaceuticals, Inc. MDGL Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported weighted average exercise price of outstanding options of $189.98 in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options increased by 72.6% year-over-year, from $110.04 to $189.98.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options?
- Over 2 years (2023 to 2025), Madrigal Pharmaceuticals, Inc.'s weighted average exercise price of outstanding options has grown at a 39.4% compound annual growth rate (CAGR), from $79.94 to $155.25.